000 01347 a2200337 4500
005 20250516235416.0
264 0 _c20150821
008 201508s 0 0 eng d
022 _a1542-6270
024 7 _a10.1177/1060028014554649
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aKrajewski, Kristin C
245 0 0 _aAchievement of therapeutic anti-Xa levels in a proven heparin-resistant patient through the use of nontraditional high-dose enoxaparin.
_h[electronic resource]
260 _bThe Annals of pharmacotherapy
_cJan 2015
300 _a130-4 p.
_bdigital
500 _aPublication Type: Case Reports; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
650 0 4 _aDrug Resistance, Neoplasm
650 0 4 _aEnoxaparin
_xadministration & dosage
650 0 4 _aFactor Xa Inhibitors
_xadministration & dosage
650 0 4 _aHeparin
_xtherapeutic use
650 0 4 _aHumans
650 0 4 _aLung Neoplasms
_xcomplications
650 0 4 _aMale
650 0 4 _aMiddle Aged
650 0 4 _aVenous Thromboembolism
_xcomplications
700 1 _aSmith, Kelly
700 1 _aConwall, Katherine
700 1 _aKrajewski, Michael P
773 0 _tThe Annals of pharmacotherapy
_gvol. 49
_gno. 1
_gp. 130-4
856 4 0 _uhttps://doi.org/10.1177/1060028014554649
_zAvailable from publisher's website
999 _c24254277
_d24254277